Rhygaze develops a novel gene therapy that targets cone cells to restore vision in patients suffering from diseases causing blindness.
Rhygaze has raised $86.0M in total funding. The most recent round was Series A. The last funding was announced in January 2025.
Rhygaze's investors include ARCH Venture Partners, Google Ventures, F-Prime, BioGeneration Ventures, Novartis Venture Fund.
Rhygaze is headquartered in Basel, Switzerland.
Rhygaze develops a novel gene therapy that targets cone cells to restore vision in patients suffering from diseases causing blindness.
Rhygaze is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Rhygaze — Funding & Investors." VCBacked, January 10, 2025, https://www.vcbacked.co/company/rhygaze. Accessed July 20, 2026.
VCBacked. (2025). Rhygaze — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/rhygaze
{{cite web |title=Rhygaze — Funding & Investors |url=https://www.vcbacked.co/company/rhygaze |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated